Quick read
The FDA is assembling a panel to discuss peptide regulation, but some experts on the panel have ties to unproven peptide advocates like RFK Jr. This could impact how peptides are regulated and used in clinical settings.
What's happening
The FDA has announced a panel to review the regulation of peptides, a move that could have significant implications for the field. However, some experts on the panel have expressed support for the use of unproven peptide chemicals, which have been championed by Robert F. Kennedy Jr. and others.
Why this matters to you
ā¢The inclusion of these experts may influence the FDA's stance on peptide regulation, potentially allowing unproven peptides to be used in clinical settings.
ā¢This development could also impact the legitimacy of peptide therapy, as some experts may be seen as promoting unproven or untested treatments.
ā¢The FDA's decision to include these experts on the panel may signal a shift in the agency's approach to regulating peptides, and could have far-reaching consequences for the field.
Let's talk about it
Do you think the inclusion of these experts on the FDA panel will impact the regulation of peptides, and potentially allow unproven peptides to be used in clinical settings?